- Home
- OTLK vs YSXT Comparison
OTLK vs YSXT Comparison
Compare OTLK & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | YSXT |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | China |
| Employees | N/A | 39 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Automotive Aftermarket |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 33.5M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | YSXT |
|---|---|---|
| Price | $0.23 | $1.10 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 76.0K |
| Earning Date | 05-14-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | ★ N/A | $5.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.93 |
| 52 Week High | $3.39 | $9.90 |
Technical Indicators
Market Signals| Indicator | OTLK | YSXT |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 47.93 |
| Support Level | $0.21 | $1.06 |
| Resistance Level | $0.29 | $1.31 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 24.53 | 59.71 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.